Linda S Wyatt

This inventor holds 9 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 6 EPO patents. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, Emory University, National Institute of Allergy and Infectious Diseases (Niaid). Active years: 2007-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Linda S Wyatt. Retrieved from https://idiyas.com/inventor/linda-s-wyatt

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 4)

% Patents Active = 66.7

CIPO Patents = 5

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 3.2

ph-index = 5

Forward Citations = 53(Granted Patents)

Company Filing History:

8 out of 3,697

The United States of America, as Represented by the Secretary, Department of Health and Human Services

National Institute of Allergy and Infectious Diseases (Niaid)

patent

4. 1 out of 196

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

patents

5. 1 out of 8,753

US Government as Represented by the Secretary of the Army

patents

where one patent can have more than one assignee

Years Active: 2007-2021

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10894966 - Virus-based expression vectors and uses thereof (2021-01-19),

2. 10421978 - Intergenic sites between conserved genes in the genome of modified vaccinia ankara (MVA) vaccinia virus (2019-09-24),

3. 9879231 - Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites (2018-01-30),

4. 9453239 - Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes (2016-09-27),

5. 9133480 - Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites (2015-09-15),

6. 9133478 - Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes (2015-09-15),

7. 8916172 - MVA expressing modified HIV envelope, gag, and pol genes (2014-12-23),

8. 7867982 - MVA expressing modified HIV envelope, gag, and pol genes (2011-01-11),

9. 7303754 - MVA expressing modified HIV envelope, gag, and pol genes (2007-12-04),

Title: Linda S Wyatt: Innovator in Virus-Based Expression Vectors

Introduction

Linda S Wyatt is a prominent inventor based in Rockville, MD (US). She has made significant contributions to the field of biotechnology, particularly in the development of virus-based expression vectors. With a total of 9 patents to her name, her work has had a profound impact on vaccine development and gene therapy.

Latest Patents

Among her latest patents is a groundbreaking invention related to virus-based expression vectors. This invention focuses on expression vectors that are ideal for vaccinating individuals against diseases using vaccinia virus and other chordopoxviruses. These vectors are designed to have high expression of recombinant genes and low expression of vector genes in target animals, while exhibiting low expression of recombinant genes and high expression of vector genes in cells used for propagation. Another notable patent involves intergenic sites between conserved genes in the genome of modified vaccinia Ankara (MVA) vaccinia virus. This invention provides new insertion sites useful for integrating exogenous sequences into an intergenic region of the vaccinia virus genome, which is crucial for developing effective medicines and vaccines.

Career Highlights

Throughout her career, Linda has worked with esteemed organizations, including the United States Department of Health and Human Services and Emory University. Her innovative research has positioned her as a leader in her field, contributing to advancements in vaccine technology and therapeutic applications.

Collaborations

Linda has collaborated with notable professionals in her field, including Bernard Moss and Patricia L Earl. These collaborations have further enhanced her research and development efforts, leading to significant advancements in biotechnology.

Conclusion

Linda S Wyatt's contributions to the field of biotechnology, particularly in virus-based expression vectors, have been invaluable. Her innovative patents and collaborations continue to influence vaccine development and gene therapy, showcasing her dedication to advancing medical science.

Profile summary based on public USPTO records.